scispace - formally typeset
Open AccessJournal ArticleDOI

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

TLDR
The data suggest that either gain or loss of MeCP2 results in gene expression changes in multiple brain regions and that some of these changes are global, which might identify subsets of genes that are more amenable to manipulation, and can thus be used to modulate some of the disease phenotypes.
Abstract
A group of post-natal neurodevelopmental disorders collectively referred to as MeCP2 disorders are caused by aberrations in the gene encoding methyl-CpG-binding protein 2 (MECP2). Loss of MeCP2 function causes Rett syndrome (RTT), whereas increased copy number of the gene causes MECP2 duplication or triplication syndromes. MeCP2 acts as a transcriptional repressor, however the gene expression changes observed in the hypothalamus of MeCP2 disorder mouse models suggest that MeCP2 can also upregulate gene expression, given that the majority of genes are downregulated upon loss of MeCP2 and upregulated in its presence. To determine if this dual role of MeCP2 extends beyond the hypothalamus, we studied gene expression patterns in the cerebellum of Mecp2-null and MECP2-Tg mice, modeling RTT and MECP2 duplication syndrome, respectively. We found that abnormal MeCP2 dosage causes alterations in the expression of hundreds of genes in the cerebellum. The majority of genes were upregulated in MECP2-Tg mice and downregulated in Mecp2-null mice, consistent with a role for MeCP2 as a modulator that can both increase and decrease gene expression. Interestingly, many of the genes altered in the cerebellum, particularly those increased by the presence of MeCP2 and decreased in its absence, were similarly altered in the hypothalamus. Our data suggest that either gain or loss of MeCP2 results in gene expression changes in multiple brain regions and that some of these changes are global. Further delineation of the expression pattern of MeCP2 target genes throughout the brain might identify subsets of genes that are more amenable to manipulation, and can thus be used to modulate some of the disease phenotypes.

read more

Citations
More filters
Journal ArticleDOI

TETonic shift: biological roles of TET proteins in DNA demethylation and transcription

TL;DR: The recent discovery that ten-eleven translocation proteins are 5-methylcytosine oxidases has provided several chemically plausible pathways for the reversal of DNA methylation, thus triggering a paradigm shift in understanding of how changes inDNA methylation are coupled to cell differentiation, embryonic development and cancer.
Journal ArticleDOI

MeCP2 Binds to 5hmC Enriched within Active Genes and Accessible Chromatin in the Nervous System

TL;DR: It is reported that 5hmC is enriched in active genes and that, surprisingly, strong depletion of 5mC is observed over these regions and these findings support a model in which5hmC and MeCP2 constitute a cell-specific epigenetic mechanism for regulation of chromatin structure and gene expression.
Journal ArticleDOI

The Cerebellum, Sensitive Periods, and Autism

TL;DR: Evidence that the cerebellum may guide the maturation of remote nonmotor neural circuitry and influence cognitive development and it is proposed that sensitive-period disruption of such internal brain communication can account for autism's key features is reviewed.

Dissection ofthemethyl-CpG binding domainfromthe chromosomal protein MeCP2

Xinsheng Nan
TL;DR: In vitro footprinting indicates that MBD binding can protect a 12 nucleotide region surrounding a methyl-CpG pair, with an approximate dissociation constant of 10(-9) M.
Journal ArticleDOI

MeCP2 binds to 5hmc enriched within active genes and accessible chromatin in the nervous system

TL;DR: In this paper, a quantitative, genome-wide analysis of 5hmC, 5-methylcytosine (5mC), and gene expression in differentiated CNS cell types in vivo is presented.
References
More filters
Journal ArticleDOI

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.

TL;DR: This study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.
Journal ArticleDOI

MeCP2, a key contributor to neurological disease, activates and represses transcription.

TL;DR: It is shown that MeCP2 associates with the transcriptional activator CREB1 at the promoter of an activated target but not a repressed target, and that it can function as both an activator and a repressor of transcription.
Journal ArticleDOI

A mouse Mecp2-null mutation causes neurological symptoms that mimic rett syndrome

TL;DR: The overlapping delay before symptom onset in humans and mice raises the possibility that stability of brain function, not brain development per se, is compromised by the absence of MeCP2, and generates mice lacking Mecp2 using Cre-loxP technology.
Journal ArticleDOI

DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation.

TL;DR: It is reported that increased synthesis of brain-derived neurotrophic factor in neurons after depolarization correlates with a decrease in CpG methylation within the regulatory region of the Bdnf gene, suggesting that DNA methylation–related chromatin remodeling is important for activity-dependent gene regulation that may be critical for neural plasticity.
Journal ArticleDOI

A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases.

TL;DR: The exclusive involvement of females, correlated with findings in family data analyses, suggests a dominant mutation on one X chromosome that results in affected girls and nonviable male hemizygous conceptuses.
Related Papers (5)